Talking Biotech With Paul Hopper - Leading ASX Executive Chairman

TL;DR

Paul Hopper, a renowned biotechnology entrepreneur, discusses his involvement in multiple biotech companies and the exciting opportunities in the biotech space.

Transcript

hey guys and welcome back to the asx investor channel very excited to be bringing to you all a special interview today today we're going to be deep diving in and exploring all things biotech we know it's a fascinating sector that attracts a lot of investor interest and we're really grateful to be joined by one of the preeminent and really renowned ... Read More

Key Insights

• 😤 The success of biotech companies relies on novel technologies and a strong leadership team.
• 😀 The biotech industry has faced challenges recently, but promising technologies and strategic partnerships offer growth opportunities.
• 🥹 Cell therapies, such as CAR-T, hold great potential in treating solid tumors.

Questions & Answers

Q: What motivated Paul Hopper to get involved in the biotech industry?

Hopper finds inspiration in working with brilliant scientists and being part of cutting-edge research that can make a transformational impact on patients and humanity.

Q: Can you explain the significance of cell therapies, particularly CAR-T, and their potential in treating solid tumors?

CAR-T therapies have been successful in treating blood cancers, but the goal is to develop CAR-T treatments for solid tumors. Hopper's companies, Imogene and Chimeric, are working on innovative approaches using oncolytic viruses and CAR-T therapies to target solid tumors.

Q: How has the journey been for Imogene, which is now worth $3 billion?

Imogene faced challenges in the early days but experienced a turning point when it acquired promising technologies. The company's success is attributed to its breakthrough results and strategic partnerships.

Q: What is the current state of the biotech industry, both in Australia and globally?

The biotech industry has seen a decline in share prices recently, but Hopper believes that promising technologies and strong leadership teams will drive future growth. He highlights the potential in radio pharmaceuticals and nuclear medicine, as big pharma companies are expected to enter this space.

Summary & Key Takeaways

• Paul Hopper is involved in executive roles at multiple biotech companies, including Imogene, Chimeric, Radio Farm, and Aravala.

• He focuses on finding and developing next-generation technologies that can make a difference in various fields, primarily in cancer oncology.

• Hopper sources technologies from major universities and hospital systems in the US, looking for innovative and promising assets.